News

The positive opinion for 2B3-101 by the COMP has specifically been granted for the treatment of glioma. As a proprietary brain-targeted version of the marketed product Caelyx/Doxil (PEG-liposomal

Creative Testing Solutions is a collaboration between Blood Systems and Florida Blood Services that offers blood and tissue facilities access to a national network of high volume donor

The exclusive world-wide development and licence agreement is based on the PolyXen PSA-Factor VIII project being developed with Baxter, a treatment of haemophilia, for improved longer-acting forms of

The findings were presented at the 15th Congress of the European Hematology Association (EHA), June 10-13, in Barcelona, Spain. According to the S*BIO 20 patients were treated at

The Phase III clinical trial is evaluating the patients under 18 to 75 years of age with refractory partial-onset seizures with or without secondary generalised seizures. Topiramate is

Nexavar (sorafenib) tablets was evaluated in patients with advanced non-squamous non-small cell lung cancer (NSCLC). NExUS evaluated Nexavar versus placebo in combination with two chemotherapeutic agents, gemcitabine and

According to Oxford BioMedica, the first cohort of patients, treated at the lowest initial dose level, have completed two-year assessments. The mean improvement from baseline in UPDRS III

Genmab holds exclusive development and commercialisation rights on 10 events out of a breast cancer database discovered using ExonHit’s genome-wide SpliceArray technology (RNA splicing analysis platform covering the

HGS said that the FDA has expressed concerns regarding the risk benefit assessment of Zalbin dosed at 900-mcg every two weeks. Although the BLA review is ongoing, HGS